Revenue and Profitability Trends
Godavari Bioref.'s net sales demonstrated variability, with a peak of ₹2,014.69 crores in March 2023, followed by a decline to ₹1,686.67 crores in March 2024, and a partial recovery to ₹1,870.25 crores in March 2025. Despite this rebound, the company’s operating profit margin (excluding other income) contracted from 7.26% in March 2023 to 5.54% in March 2025, signalling margin pressures amid fluctuating sales.
Operating profit (PBDIT) also declined from ₹154.62 crores in March 2023 to ₹120.31 crores in March 2025, reflecting increased expenditure pressures. Notably, raw material costs showed a downward trend from ₹1,533.15 crores in March 2024 to ₹1,242.75 crores in March 2025, which may have partially cushioned margin erosion.
However, the company faced a significant setback in profitability, reporting a consolidated net loss of ₹23.41 crores in March 2025, a reversal from profits of ₹19.64 crores and ₹12.30 crores in the preceding two years. This loss was accompanied by a negative earnings per share (EPS) of ₹-4.57 in March 2025, compared to positive EPS figures previously.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Cost Structure and Expense Analysis
The company’s total expenditure excluding depreciation decreased from ₹1,868.46 crores in March 2023 to ₹1,766.60 crores in March 2025, indicating some cost control efforts. Employee costs rose modestly over this period, reaching ₹125.35 crores in March 2025, while other expenses declined from ₹367.89 crores in March 2023 to ₹256.09 crores in March 2025.
Interest expenses remained relatively stable, hovering around ₹72 crores to ₹75 crores, which, combined with depreciation charges, contributed to a shrinking gross profit before tax. The company’s profit before tax turned negative in March 2025, underscoring the financial strain.
Balance Sheet and Financial Position
On the balance sheet front, Godavari Bioref. has shown steady growth in shareholder’s funds, rising from ₹489.45 crores in March 2023 to ₹781.96 crores in March 2025. This increase was supported by a significant rise in reserves, which nearly doubled from ₹447.50 crores to ₹730.79 crores over the same period.
Conversely, the company’s total debt has been on a declining trend, falling from ₹735.34 crores in March 2023 to ₹489.41 crores in March 2025, reflecting deleveraging efforts. Long-term borrowings notably decreased, while short-term borrowings remained relatively stable.
Asset-wise, net block values remained fairly consistent, around ₹860 crores, while current assets increased to over ₹1,023 crores in March 2025. The company’s net current assets improved to ₹139 crores, a positive sign compared to a negative position in the previous year.
Considering Godavari Bioref.? Wait! SwitchER has found potentially better options in FMCG and beyond. Compare this Smallcap with top-rated alternatives now!
- - Better options discovered
- - FMCG + beyond scope
- - Top-rated alternatives ready
Cash Flow and Liquidity Overview
Cash flow from operating activities has shown a sharp decline, dropping from ₹196 crores in March 2023 to just ₹6 crores in March 2025. This contraction reflects the challenges in generating cash from core operations. Investing activities consistently resulted in cash outflows, with ₹68 crores spent in March 2025, primarily on capital expenditure and asset development.
Financing activities in March 2025 contributed a positive inflow of ₹63 crores, contrasting with outflows in the previous year, indicating some fresh capital or debt restructuring. Despite these movements, the net cash inflow remained minimal at ₹1 crore in March 2025, with closing cash and cash equivalents stable at ₹12 crores.
Summary and Investor Implications
Overall, Godavari Bioref. has experienced a challenging period marked by revenue fluctuations, margin pressures, and a return to net losses in the latest fiscal year. The company’s balance sheet shows improvement through increased reserves and reduced debt, which may provide a foundation for future stability. However, the sharp decline in operating cash flow and negative profitability highlight ongoing operational challenges.
Investors should weigh these mixed signals carefully, considering both the company’s efforts to strengthen its financial position and the risks posed by recent losses and cash flow constraints. Monitoring upcoming quarterly results and strategic initiatives will be crucial to assess the company’s recovery trajectory and long-term value creation potential.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
